Vanguard Capital Management
RARE icon

Vanguard Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Vanguard Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143M Buy
4,296,491
+106,660
+3% +$2.65M ﹤0.01% 1343
2026
Q1 		$87.8M Buy
+4,189,831
New +$94.3M ﹤0.01% 1546

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's RARE Position: Q2 2026 in Review

Vanguard Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 2.5% in Q2 2026, buying an estimated $2.65M and bringing the position to 4,296,491 shares worth $143M. The position accounts for ﹤0.01% of the portfolio, ranked #1343.

Vanguard Capital Management first reported a position in RARE in Q1 2026 and has held it in 2 quarters since. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Vanguard Capital Management held 4,296,491 shares of Ultragenyx Pharmaceutical worth $143M as of Q2 2026.
  • Vanguard Capital Management bought 106,660 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.65M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1343 holding.
  • Vanguard Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.